Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

‘Non-answers’ aren’t working. This is what investors really need from the Fed. October 24, 2026
What really matters to investors, economists say, is for Fed Chairman Kevin Warsh to prove he can successfully communicate the central bank’s strategy.
Greg Robb
Do machines have feelings? AI has philosophers and tech leaders rethinking consciousness. October 24, 2026
As AI models become more advanced, tech leaders and philosophers are mulling the relationship between humanity and technology.
Christine Ji
‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me? October 24, 2026
“My late father bought our house for $250,000 in the 1990s.”
Quentin Fottrell
My spouse was awarded $90,000 from my 401(k) in our divorce. How is that fair? October 24, 2026
“I retired in 2020 and subsequently went through a divorce a few years later.”
Quentin Fottrell
‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad? October 23, 2026
“I married a wonderful man with a good income. He left his job due to health issues and suffered a massive stroke at 53.”
Quentin Fottrell
Will Anthropic pull off a November IPO? Time is running out to file key paperwork. October 23, 2026
If market pressures keep building, Anthropic “could reasonably decide it is better to stay private and wait for a better opportunity,” one portfolio manager says.
William Gavin
Investors piled a record sum into a leveraged semiconductor ETF last week. Things didn’t work out. October 23, 2026
Traders making bullish bets on chip stocks are getting walloped this month, as renewed fears emerged about investment returns on the buildout of artificial intelligence.
Christine Idzelis
This hot AI-fueled stock has been in a rut. It just beat earnings expectations by 36%. October 23, 2026
A company beating earnings expectations by 36% and revenue expectations by 15% would usually see a postresults bump. But not for Bloom Energy, the fuel-cell maker that has flourished due to data-center demand.
Steve Goldstein
The mobile ambitions of SpaceX are hitting telecom stocks again. Here’s what the latest developments mean. October 23, 2026
Reports of Starlink’s discussions with cell-tower owners were noticed by shareholders of Verizon, AT&T and T-Mobile.
Jules Rimmer
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term. October 23, 2026
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Jaimy Lee